Core Viewpoint - Puma Biotechnology will host a conference call on February 26, 2026, to discuss its fourth quarter and full year 2025 financial results, following the release of these results [1]. Company Overview - Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing innovative products to enhance cancer care [1]. - The company in-licensed the global development and commercialization rights to PB272 (neratinib) in 2011, which was approved by the FDA in 2017 for treating early stage HER2-overexpressed/amplified breast cancer [1]. - Neratinib is marketed in the U.S. as NERLYNX® and has received additional FDA approvals for various cancer treatments [1]. Recent Developments - In September 2022, Puma entered into an exclusive license agreement for the anti-cancer drug alisertib, focusing on small cell lung cancer and breast cancer [1]. - The company initiated a Phase II clinical trial for alisertib monotherapy in February 2024 and another trial in November 2024 for its combination with endocrine therapy [1]. - Puma Biotechnology was added to the Nasdaq Biotechnology Index effective after the close of trading on December 19, 2025 [1].

Core Insights - Er-Kim has signed an agreement with Puma Biotechnology to commercialize NERLYNX in select Eastern European and Central Asian countries [1][2] - NERLYNX is a treatment for HER2-positive breast cancer, approved for both early-stage and metastatic cases [3][7] - Breast cancer is the most common cancer among women globally, with 2.3 million new cases and 670,000 deaths reported in 2022 [4] Company Overview - Er-Kim, established in 1981, partners with over 40 global leaders and has revenues exceeding EUR 260 million, reaching over 600 million patients [6] - Puma Biotechnology focuses on developing innovative cancer care products and has successfully commercialized NERLYNX since its FDA approval in 2017 [7] Market Context - The agreement aims to improve access to NERLYNX in Russia and the Commonwealth of Independent States, addressing the disparity in treatment availability for breast cancer [5] - The burden of breast cancer varies significantly across different regions, highlighting the need for targeted treatment solutions [4][5]